FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234181567> ?p ?o ?g. }

• W4234181567 endingPage "2149" @default.
• W4234181567 startingPage "2139" @default.
• W4234181567 abstract "MUC-1/DF-3 remains an attractive target for vaccine therapy. It is overexpressed in the majority of human carcinomas and multiple myeloma. Clinical trials using MUC-1-based vaccines have demonstrated safety, clinical responses, and the induction of T-cell responses directed against MUC-1. Previous studies in experimental models and in clinical trials have demonstrated that altering the amino acid sequence of a self epitope can lead to the generation of an enhancer agonist epitope capable of eliciting stronger T-cell responses than the native epitope can.We describe here the identification of six novel class I HLA-A2 epitopes of MUC-1 that reside outside of the variable number of tandem repeat region. Each is shown to have the ability to activate human T cells as measured by IFN-gamma production. One epitope (ATWGQDVTSV, at amino acid position 92-101 and designated P-92), which demonstrated the highest level of binding to HLA-A2 and which induced the highest level of IFN-gamma in human T cells, was further studied for the generation of potential enhancer agonist epitopes. Of four potential agonists identified, one epitope (ALWGQDVTSV, designated P-93L) was identified as an enhancer agonist. Compared with the native P-92 peptide, the P-93L agonist (a). bound HLA-A2 at lower peptide concentrations, (b). demonstrated a higher avidity for HLA-A2 in dissociation assays, (c). when used with antigen-presenting cells, induced the production of more IFN-gamma by T cells than with the use of the native peptide, and (d). was capable of more efficiently generating MUC-1-specific human T-cell lines from normal volunteers and pancreatic cancer patients. Most importantly, the T-cell lines generated using the agonist epitope were more efficient than those generated with the native epitope in the lysis of targets pulsed with the native epitope and in the lysis of HLA-A2 human tumor cells expressing MUC-1.In addition to the identification of novel MUC-1 epitopes outside the variable number of tandem repeat region, the studies reported here describe the first agonist epitope of MUC-1. The employment of this agonist epitope in peptide-, protein-, and vector-based vaccines may well aid in the development of effective vaccines for a range of human cancers." @default.
• W4234181567 created "2022-05-12" @default.
• W4234181567 creator A5018956979 @default.
• W4234181567 creator A5059931764 @default.
• W4234181567 creator A5070669850 @default.
• W4234181567 creator A5073536820 @default.
• W4234181567 creator A5081826448 @default.
• W4234181567 date "2004-03-15" @default.
• W4234181567 modified "2023-10-13" @default.
• W4234181567 title "A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1" @default.
• W4234181567 cites W1445322489 @default.
• W4234181567 cites W1481917640 @default.
• W4234181567 cites W1541668845 @default.
• W4234181567 cites W1595402802 @default.
• W4234181567 cites W1624931691 @default.
• W4234181567 cites W1671377935 @default.
• W4234181567 cites W1892119656 @default.
• W4234181567 cites W1905156984 @default.
• W4234181567 cites W1969057879 @default.
• W4234181567 cites W1976018155 @default.
• W4234181567 cites W1979397217 @default.
• W4234181567 cites W2002038445 @default.
• W4234181567 cites W2012148175 @default.
• W4234181567 cites W2013686456 @default.
• W4234181567 cites W2014428384 @default.
• W4234181567 cites W2020115881 @default.
• W4234181567 cites W2020814485 @default.
• W4234181567 cites W2021014181 @default.
• W4234181567 cites W2022130479 @default.
• W4234181567 cites W2023707348 @default.
• W4234181567 cites W2023761151 @default.
• W4234181567 cites W2034136192 @default.
• W4234181567 cites W2037910203 @default.
• W4234181567 cites W2049871389 @default.
• W4234181567 cites W2050989136 @default.
• W4234181567 cites W2052714233 @default.
• W4234181567 cites W2053853693 @default.
• W4234181567 cites W2058011770 @default.
• W4234181567 cites W2059637973 @default.
• W4234181567 cites W2059833802 @default.
• W4234181567 cites W2060358477 @default.
• W4234181567 cites W2079542677 @default.
• W4234181567 cites W2083249852 @default.
• W4234181567 cites W2103885797 @default.
• W4234181567 cites W2131761283 @default.
• W4234181567 cites W2142066580 @default.
• W4234181567 cites W2160808357 @default.
• W4234181567 cites W2247920240 @default.
• W4234181567 cites W4230341237 @default.
• W4234181567 cites W4237417657 @default.
• W4234181567 cites W4255074917 @default.
• W4234181567 doi "https://doi.org/10.1158/1078-0432.ccr-1011-03" @default.
• W4234181567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15041735" @default.
• W4234181567 hasPublicationYear "2004" @default.
• W4234181567 type Work @default.
• W4234181567 citedByCount "54" @default.
• W4234181567 countsByYear W42341815672012 @default.
• W4234181567 countsByYear W42341815672013 @default.
• W4234181567 countsByYear W42341815672014 @default.
• W4234181567 countsByYear W42341815672015 @default.
• W4234181567 countsByYear W42341815672016 @default.
• W4234181567 countsByYear W42341815672017 @default.
• W4234181567 countsByYear W42341815672018 @default.
• W4234181567 countsByYear W42341815672019 @default.
• W4234181567 countsByYear W42341815672020 @default.
• W4234181567 countsByYear W42341815672021 @default.
• W4234181567 countsByYear W42341815672022 @default.
• W4234181567 crossrefType "journal-article" @default.
• W4234181567 hasAuthorship W4234181567A5018956979 @default.
• W4234181567 hasAuthorship W4234181567A5059931764 @default.
• W4234181567 hasAuthorship W4234181567A5070669850 @default.
• W4234181567 hasAuthorship W4234181567A5073536820 @default.
• W4234181567 hasAuthorship W4234181567A5081826448 @default.
• W4234181567 hasBestOaLocation W42341815671 @default.
• W4234181567 hasConcept C104317684 @default.
• W4234181567 hasConcept C147483822 @default.
• W4234181567 hasConcept C153911025 @default.
• W4234181567 hasConcept C154317977 @default.
• W4234181567 hasConcept C159047783 @default.
• W4234181567 hasConcept C167625842 @default.
• W4234181567 hasConcept C170493617 @default.
• W4234181567 hasConcept C179223381 @default.
• W4234181567 hasConcept C188280979 @default.
• W4234181567 hasConcept C19317047 @default.
• W4234181567 hasConcept C195616568 @default.
• W4234181567 hasConcept C202751555 @default.
• W4234181567 hasConcept C203014093 @default.
• W4234181567 hasConcept C2776090121 @default.
• W4234181567 hasConcept C2778938600 @default.
• W4234181567 hasConcept C2779281246 @default.
• W4234181567 hasConcept C55493867 @default.
• W4234181567 hasConcept C78598654 @default.
• W4234181567 hasConcept C86803240 @default.
• W4234181567 hasConcept C8891405 @default.
• W4234181567 hasConceptScore W4234181567C104317684 @default.
• W4234181567 hasConceptScore W4234181567C147483822 @default.
• W4234181567 hasConceptScore W4234181567C153911025 @default.
• W4234181567 hasConceptScore W4234181567C154317977 @default.

• next